No revenue or earnings to evaluate; the stock is a binary event driven by YB-101 Phase 2a data in H2 2027. Monitor enrollment updates and any data readouts from GenSci's Phase 1 MAD trial in TED, also expected H2 2027.
Drug in focus
YARW drug pipeline →YB-101
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2a/2b (dosing initiated ~July 27, 2026); Phase 1 SAD in thyroid eye disease previously reported
- Time to market
- Unknown — mid-stage. If the Phase 2a/2b trial succeeds and later registrational studies follow, approval would be several years away (late 2020s at the earliest); the company currently has no approved products.
- Next catalyst
- None dated
What to watchYB-101 is a Phase 2a/2b, single-asset bet at a company (Nasdaq: YARW, formerly VYNE) that just closed a reverse merger, raised ~$200M, and began dosing the pivotal-to-next-stage trial, but the defining data readout is not expected until 2H 2027. A non-medical investor should treat YARW as a speculative, liquidity-thin clinical stock: watch for interim Phase 2a/2b data, the exact readout date, and any competitive readouts from anti-FcRn/IgG-degrading drugs in Graves'/thyroid eye disease.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $19.63entry
- T+1 · 4d ago −8.15%α −7.79% · $18.03
- T+2 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Yarrow Bioscience reported Q3 2026 net loss of $9.7M ($0.43 per share) with no revenue, as a pre-revenue clinical-stage biotech. The key event is the ongoing Phase 2a DIRECTION-GD trial for YB-101 in Graves disease, with topline results expected in H2 2027. The company completed a $172.5M public offering in September 2026, extending cash runway into 2030.
Key Financial Metrics
Key Facts
- Net loss of $9.7 million for Q3 2026, or $0.43 per share
- Cash and cash equivalents of $268.9 million as of September 30, 2026
- Completed approximately $172.5 million underwritten public offering in September 2026
- Enrollment ongoing in Phase 2a portion of DIRECTION-GD trial for YB-101
- Phase 2a topline results expected in second half of 2027
- Cash runway expected to fund operations into 2030
- 11.5 million common shares and 23.7 million pre-funded warrants outstanding as of September 30, 2026
Financial Impact
Net loss $9.7M; cash position $268.9M post-$172.5M offering
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- Phase 2a data for YB-101 not expected until H2 2027, creating binary event risk
- Significant dilution from 23.7M pre-funded warrants outstanding
- Prior clinical hold on VYN202 (legacy VYNE asset) highlights regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001566044-26-000017 |
| Document: yarw-20261112.htm | 0001566044-26-000017 |
| Document: 0001566044-26-000017-index-headers.html | 0001566044-26-000017 |
| Document: 0001566044-26-000017-index.html | 0001566044-26-000017 |
| Document: 0001566044-26-000017.txt | 0001566044-26-000017 |
| 8-K Data (Synthetic) | 0001566044-26-000017 |
Track record
13 reports on YARW
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.20 Now $14.27 +0.49% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $15.44 Now $14.27 −7.58% settles Dec 15
- Nov 16, 20261d ago SC 13G Neutral 3/10 Entry $18.20 Now $14.27 −21.59% settles Dec 15
- Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $17.35 Now $14.27 −17.75% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
- Nov 12, 20265d ago 8-K Neutral 4/10 Viewing Entry $19.63 Now $14.27 −27.31% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers